Sitafloxacin
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H18ClF2N3O3 |
Molar mass | 409.82 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic[1] that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.[citation needed]
See also
References
- ^ Anderson DL (July 2008). "Sitafloxacin hydrate for bacterial infections". Drugs of Today. 44 (7): 489–501. doi:10.1358/dot.2008.44.7.1219561. PMID 18806900.
Further reading
- Keating GM (April 2011). "Sitafloxacin: in bacterial infections". Drugs. 71 (6): 731–44. doi:10.2165/11207380-000000000-00000. PMID 21504249. S2CID 195688876.
External links
- (in Japanese) Gracevit グレースビット (PDF) Daiichi Sankyo Co. January 2008.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- Articles with changed KEGG identifier
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All articles with unsourced statements
- Articles with unsourced statements from January 2023
- Articles with Japanese-language sources (ja)
- All stub articles
- Antibiotic stubs
- Fluoroquinolone antibiotics
- Chloroarenes
- Cyclopropanes
- Organofluorides
- Spiro compounds
- Daiichi Sankyo